How Exercise and a Bone-Building Drug May Work Together in Type 1 Diabetes

People with type 1 diabetes often experience changes in muscle structure and function as part of the disease. Muscles rely on healthy mitochondria—tiny structures that produce energy—to work properly. When diabetes affects muscle ultrastructure (the tiny internal organization of muscle cells), it can impact strength, function, and overall quality of life.

Researchers are looking for ways to protect and improve muscle health in type 1 diabetes. A new study examined whether combining exercise with teriparatide, a medication typically used to treat bone loss, might offer benefits for muscle tissue.

Scientists used Akita mice, a model of type 1 diabetes, to compare four groups: a control group, mice that exercised, mice that received teriparatide injections, and mice that received both treatments together. The teriparatide was given three times per week for six weeks, while exercise occurred five days per week on a treadmill.

Researchers measured multiple markers of muscle health, including blood sugar levels, muscle weight, grip strength, and the actual structure of muscle fibers and mitochondria viewed under electron microscopes. They also examined gene expression to understand what was happening at the cellular level.

Mice that received both teriparatide and exercise showed the greatest reduction in fasting blood glucose compared to other groups. Their muscles also showed increased weight relative to tibial (shin bone) length, suggesting improved muscle mass.

Under the electron microscope, mitochondria in the combined treatment group appeared noticeably larger than in other groups. The study also found structural changes in the sarcomeres (the repeating contractile units of muscle fibers) in the combined treatment group.

Interestingly, other measures—including grip strength, overall muscle fiber size, and mitochondrial number—did not show clear differences among groups. This suggests that the combination therapy may have produced specific structural changes rather than broad improvements across all muscle parameters.

This research offers an early glimpse into how teriparatide and exercise might work together to influence muscle structure in type 1 diabetes. The finding that the combination produced greater blood sugar reduction than either treatment alone is noteworthy and worth further investigation.

However, this was a small study in mice, not people. Before teriparatide could be considered for muscle health in type 1 diabetes, researchers would need to conduct human studies to determine whether these structural changes translate to meaningful health benefits, how the treatment would be tolerated, and whether results would be consistent across diverse patient populations.

For now, this study highlights the potential value of combining different approaches—medication plus lifestyle—in managing type 1 diabetes. It also reinforces what many already know: exercise remains a cornerstone of diabetes care and overall health.

Source: In vivo (Athens, Greece). Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.